Newly listed Verve Therapeutics, Graphite Bio jump on Intellia breakthrough
28/06/2021 15:53
** Verve Therapeutics VERV.O and Graphite Bio GRPH.O ,
which both went public this month, jump on Mon in wake of
Intellia Therapeutics' NTLA.O breakthrough news
** Intellia and partner Regeneron Pharma REGN.O over the
weekend posted positive interim data from ongoing early-stage
trial for genome editing candidate, NTLA-2001 urn:newsml:reuters.com:*:nL3N2OA2N8
** NTLA-2001 is the first CRISPR/Cas9-based therapy
candidate for precision editing of a gene in a target tissue in
humans
** VERV jumps 33.0% to $47.85. Shares of gene editing firm
focused on treating cardiovascular diseases now ~150% above Jun
16 IPO price of $19 urn:newsml:reuters.com:*:nL3N2NZ432
** GRPH rises 12.2% to $20.75, after closing up ~9% at
$18.50 in debut on Fri. CRISPR specialist raised $238 mln in IPO
priced at $17, and plans to use proceeds to launch Phase 1/2
clinical trial for its lead drug to treat sickle cell disease
later this year (See filing https://www.sec.gov/Archives/edgar/data/1815776/000119312521200751/d132211d424b4.htm#toc132211_5)
(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 1-332-219-1430))